Epiomic Epidemiology Series: Growth Hormone Deficiency Forecast in 9 Major Markets 2016-2026

Date: 2016-10

” Epidemiology Series Forecast Report on Growth Hormone Deficiency (GHD) in 9 Major Markets
Growth Hormone Deficiency (GHD) results from the destruction of normal pituitary and hypothalamic tissue and is characterized by the inadequate secretion of growth hormone (GH), from the anterior pituitary gland. GHD can occur at any point during an individual’s life, but is primarily defined as being of Childhood onset (CO) or Adult onset (AO). The majority of CO is congenital whereas AO forms tend to be acquired or idiopathic.
This report provides the current prevalent population for GHD across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, India and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of GHD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for GHD include:
• Diabetes Mellitus & other issues with glucose regulation (including IGT and metabolic syndrome)
• Hypertension
• Obesity
• Osteopenia, osteoporosis & increased fractures
• Liver disease
• Cerebrovascular diseases
• Cardiovascular diseases
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global GHD’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of GHD and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on GHD’s prevalent population.
• Identify sub-populations within GHD which require treatment.
• Gain an understanding of the specific markets that have the largest number of GHD patients.

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample